Accretion Pharmaceuticals IPO GMP and Details
The Accretion Pharmaceuticals IPO GMP (Grey Market Premium) is gaining attention among SME investors. While the official listing is on the NSE SME platform, the grey market trend gives an early idea of investor sentiment and expected listing gain. GMP refers to the premium amount investors are willing to pay over the IPO price before the stock lists publicly.
Accretion Pharmaceuticals Ltd, based in Gujarat, manufactures and markets a wide range of pharmaceutical products including tablets, capsules, syrups, ointments, and herbal formulations. The company exports to over 20 countries and holds certifications like WHO-GMP, showing strong operational credibility.
The IPO opens on May 14, 2025, and closes on May 16, 2025, with an issue size of ₹29.75 crore. It offers 29.46 lakh equity shares and follows the book-built issue method. The company reported a total income of ₹33.94 lakh and profit after tax of ₹3.88 lakh in FY 2024.
Funds raised will support equipment purchase, office upgrades, working capital, and debt repayment. While the Accretion Pharmaceuticals IPO GMP gives a glimpse of expected market response, investors should also review financials, valuation, and risk factors before applying.
Comments
0 comment